European Journal of Nuclear Medicine and Molecular Imaging

Article	Citations
18F-FDG brain PET hypometabolism in patients with long COVID	263
E-PSMA: the EANM standardized reporting guidelines v1.0 for PSMA-PET	184
Usefulness of [68Ga]Ga-DOTA-FAPI-04 PET/CT in patients presenting with inconclusive [18F]FDG PET/CT findings	149
International recommendations for personalised selective internal radiation therapy of primary and metastatic liver diseases with yttrium-90 resin microspheres	140
EANM practice guideline/SNMMI procedure standard for dopaminergic imaging in Parkinsonian syndromes 1.0	130
Clinical performance of long axial field of view PET/CT: a head-to-head intra-individual comparison of the Biograph Vision Quadra with the Biograph Vision PET/CT	127
18F-FDG brain PET hypometabolism in post-SARS-CoV-2 infection: substrate for persistent/delayed disorders?	120
Fibroblast activation protein inhibitor (FAPI) PET for diagnostics and advanced targeted radiotherapy in head and neck cancers	114
Consensus statements on PSMA PET/CT response assessment criteria in prostate cancer	114
The EANM practice guidelines for parathyroid imaging	113
Head-to-head intra-individual comparison of biodistribution and tumor uptake of 68Ga-FAPI and 18F-FDG PET/CT in cancer patients	112
Long COVID hallmarks on [18F]FDG-PET/CT: a case-control study	102
Imaging fibroblast activation protein in liver cancer: a single-center post hoc retrospective analysis to compare [68Ga]Ga-FAPI-04 PET/CT versus MRI and [18F]-FDG PET/CT	97
Vasculitis changes in COVID-19 survivors with persistent symptoms: an [18F]FDG-PET/CT study	96
The cerebral network of COVID-19-related encephalopathy: a longitudinal voxel-based 18F-FDG-PET study	95
Histologic subtype classification of non-small cell lung cancer using PET/CT images	93
Hypermetabolic lymphadenopathy following administration of BNT162b2 mRNA Covid-19 vaccine: incidence assessed by [18F]FDG PET-CT and relevance to study interpretation	93
68Ga-FAPI-PET/CT in patients with various gynecological malignancies	90
Kinetic modeling and parametric imaging with dynamic PET for oncological applications: general considerations, current clinical applications, and future perspectives	87
Comparison of PET imaging of activated fibroblasts and 18F-FDG for diagnosis of primary hepatic tumours: a prospective pilot study	86
Automated detection and quantification of COVID-19 pneumonia: CT imaging analysis by a deep learning-based software	86
Biodistribution, pharmacokinetics, dosimetry of [68Ga]Ga-DOTA.SA.FAPi, and the head-to-head comparison with [18F]F-FDG PET/CT in patients with various cancers	86
The validation status of blood biomarkers of amyloid and phospho-tau assessed with the 5-phase development framework for AD biomarkers	83
PET/MRI in prostate cancer: a systematic review and meta-analysis	83
Deep learning-assisted ultra-fast/low-dose whole-body PET/CT imaging	83

Cellular sources of TSPO expression in healthy and diseased brain	83
EANM procedure guidelines for brain PET imaging using [18F]FDG, version 3	81
Machine learning-based analysis of [18F]DCFPyL PET radiomics for risk stratification in primary prostate cancer	80
State-of-the-art of FAPI-PET imaging: a systematic review and meta-analysis	80
Correlation of Y90-absorbed radiation dose to pathological necrosis in hepatocellular carcinoma: confirmatory multicenter analysis in 45 explants	78
A theranostic approach of [68Ga]Ga-DOTA.SA.FAPi PET/CT-guided [177Lu]Lu-DOTA.SA.FAPi radionuclide therapy in an end-stage breast cancer patient: new frontier in targeted radionuclide therapy	76
Fibroblast activation protein targeted therapy using [177Lu]FAPI-46 compared with [225Ac]FAPI-46 in a pancreatic cancer model	75
Role of [68Ga]Ga-DOTA-FAPI-04 PET/CT in the evaluation of peritoneal carcinomatosis and comparison with [18F]-FDG PET/CT	75
EANM procedure guideline for the treatment of liver cancer and liver metastases with intra-arterial radioactive compounds	73
EANM dosimetry committee recommendations for dosimetry of 177Lu-labelled somatostatin-receptor- and PSMA-targeting ligands	73
Fibroblast imaging of hepatic carcinoma with 68Ga-FAPI-04 PET/CT: a pilot study in patients with suspected hepatic nodules	73
PSMA PET total tumor volume predicts outcome of patients with advanced prostate cancer receiving [177Lu]Lu-PSMA-617 radioligand therapy in a bicentric analysis	72
Supervised machine learning enables non-invasive lesion characterization in primary prostate cancer with [68Ga]Ga-PSMA-11 PET/MRI	72
Deep-JASC: joint attenuation and scatter correction in whole-body 18F-FDG PET using a deep residual network	72
Prior therapies as prognostic factors of overall survival in metastatic castration-resistant prostate cancer patients treated with [177Lu]Lu-PSMA-617. A WARMTH multicenter study (the 617 trial)	72
The image quality, lesion detectability, and acquisition time of 18F-FDG total-body PET/CT in oncological patients	69
COVID-19 pandemic: guidance for nuclear medicine departments	69
Fully automatic segmentation of diffuse large B cell lymphoma lesions on 3D FDG-PET/CT for total metabolic tumour volume prediction using a convolutional neural network.	67
EANM procedural guidelines for PET/CT quantitative myocardial perfusion imaging	66
Focal unspecific bone uptake on [18F]-PSMA-1007 PET: a multicenter retrospective evaluation of the distribution, frequency, and quantitative parameters of a potential pitfall in prostate cancer imagin	64
Total-body PET/CT using half-dose FDG and compared with conventional PET/CT using full-dose FDG in lung cancer	64
PSMA PET/CT: joint EANM procedure guideline/SNMMI procedure standard for prostate cancer imaging 2.0	63
18F-FDG PET baseline radiomics features improve the prediction of treatment outcome in diffuse large B-cell lymphoma	62
PSMA radioligand therapy for solid tumors other than prostate cancer: background, opportunities, challenges, and first clinical reports	62
Clinical translational evaluation of Al18F-NOTA-FAPI for fibroblast activation protein-targeted tumour imaging	62
Head-to-head comparison of [68Ga]Ga-FAPI-04 and [18F]-FDG PET/CT in evaluating the extent of disease in gastric adenocarcinoma	61
HER2-directed antibodies, affibodies and nanobodies as drug-delivery vehicles in breast cancer with a specific focus on radioimmunotherapy and radioimmunoimaging	61
EANM position paper on article 56 of the Council Directive 2013/59/Euratom (basic safety standards) for nuclear medicine therapy	61
Decoding COVID-19 pneumonia: comparison of deep learning and radiomics CT image signatures	61
A head-to-head comparison of 68Ga-DOTA-FAPI-04 and 18F-FDG PET/MR in patients with nasopharyngeal carcinoma: a prospective study	61
The value of 18F-FDG PET/CT for predicting or monitoring immunotherapy response in patients with metastatic melanoma: a systematic review and meta-analysis	60
End-to-end automatic differentiation of the coronavirus disease 2019 (COVID-19) from viral pneumonia based on chest CT	60
Preclinical evaluation of FAP-2286 for fibroblast activation protein targeted radionuclide imaging and therapy	58
Brain 18F-FDG PET for the diagnosis of autoimmune encephalitis: a systematic review and a meta-analysis	58
[153Sm]Samarium-labeled FAPI-46 radioligand therapy in a patient with lung metastases of a sarcoma	58
Prognostic implications of dual tracer PET/CT: PSMA ligand and [18F]FDG PET/CT in patients undergoing [177Lu]PSMA radioligand therapy	57
[18F]AlF-NOTA-octreotide PET imaging: biodistribution, dosimetry and first comparison with [68Ga]Ga-DOTATATE in neuroendocrine tumour patients	57
Pelvic lymph-node staging with 18F-DCFPyL PET/CT prior to extended pelvic lymph-node dissection in primary prostate cancer - the SALT trial -	57
Procedural recommendations of cardiac PET/CT imaging: standardization in inflammatory-, infective-, infiltrative-, and innervation (4Is)-related cardiovascular diseases: a joint collaboration of the E	56
The indispensable role of chest CT in the detection of coronavirus disease 2019 (COVID-19)	56
Value of [68Ga]Ga-FAPI-04 imaging in the diagnosis of renal fibrosis	56
Radiomics analysis of [18F]FDG PET/CT for microvascular invasion and prognosis prediction in very-early- and early-stage hepatocellular carcinoma	55
Comparing the diagnostic performance of radiotracers in recurrent prostate cancer: a systematic review and network meta-analysis	55
Diagnostic value of [18F]FDG-PET/CT for treatment monitoring in large vessel vasculitis: a systematic review and meta-analysis	54
FDG-PET/CT findings highly suspicious for COVID-19 in an Italian case series of asymptomatic patients	54
Similar patterns of [18F]-FDG brain PET hypometabolism in paediatric and adult patients with long COVID: a paediatric case series	54
Improved cancer detection in Waldeyer’s tonsillar ring by 68Ga-FAPI PET/CT imaging	53
Ultra-low-activity total-body dynamic PET imaging allows equal performance to full-activity PET imaging for investigating kinetic metrics of 18F-FDG in healthy volunteers	53
Effect of machine learning re-sampling techniques for imbalanced datasets in 18F-FDG PET-based radiomics model on prognostication performance in cohorts of head and neck cancer patients	53
Long axial field of view PET scanners: a road map to implementation and new possibilities	53

The potential utility of [68 Ga]Ga-DOTA-FAPI-04 as a novel broad-spectrum oncological and non-oncological imaging agent—comparison with [18F]FDG	52
Radiomics and gene expression profile to characterise the disease and predict outcome in patients with lung cancer	51
[11C]MODAG-001—towards a PET tracer targeting α-synuclein aggregates	51
Transpathology: molecular imaging-based pathology	51
Comparison of [68 Ga]Ga-FAPI-04 and [18F]-FDG for the detection of primary and metastatic lesions in patients with gastric cancer: a bicentric retrospective study	51
68Ga-labelled desferrioxamine-B for bacterial infection imaging	50
Diagnostic value of [18F]FDG-PET/CT in polymyalgia rheumatica: a systematic review and meta-analysis	50
Multi-scale optoacoustic molecular imaging of brain diseases	50
Whole-body voxel-based internal dosimetry using deep learning	50
Clinical utility of [68Ga]Ga-labeled fibroblast activation protein inhibitor (FAPI) positron emission tomography/computed tomography for primary staging and recurrence detection in nasopharyngeal carc	49
Co-clinical FDG-PET radiomic signature in predicting response to neoadjuvant chemotherapy in triple-negative breast cancer	49
[18F]FAPI-42 PET imaging in cancer patients: optimal acquisition time, biodistribution, and comparison with [68Ga]Ga-FAPI-04	49
CXCR4-targeted theranostics in oncology	48
Positron emission tomography and computed tomography with [68Ga]Ga-fibroblast activation protein inhibitors improves tumor detection and staging in patients with pancreatic cancer	48
Joint EANM/SNMMI/ANZSNM practice guidelines/procedure standards on recommended use of [18F]FDG PET/CT imaging during immunomodulatory treatments in patients with solid tumors version 1.0	48
[68Ga]Ga-DOTA-FAPI-04 PET/CT imaging in a case of prostate cancer with shoulder arthritis	47
Individual brain metabolic connectome indicator based on Kullback-Leibler Divergence Similarity Estimation predicts progression from mild cognitive impairment to Alzheimer’s dementia	47
68Ga-PSMA PET/CT tumour intensity pre-operatively predicts adverse pathological outcomes and progression-free survival in localised prostate cancer	47
Structural and functional radiomics for lung cancer	46
Large language models (LLM) and ChatGPT: what will the impact on nuclear medicine be?	46
First results on kinetic modelling and parametric imaging of dynamic 18F-FDG datasets from a long axial FOV PET scanner in oncological patients	45
68Ga-PSMA PET/CT targeted biopsy for the diagnosis of clinically significant prostate cancer compared with transrectal ultrasound guided biopsy: a prospective randomized single-centre study	45
What’s behind 68Ga-PSMA-11 uptake in primary prostate cancer PET? Investigation of histopathological parameters and immunohistochemical PSMA expression patterns	44
Baseline PET/CT imaging parameters for prediction of treatment outcome in Hodgkin and diffuse large B cell lymphoma: a systematic review	44
Hybrid total-body pet scanners—current status and future perspectives	44
Clinical summary of fibroblast activation protein inhibitor-based radiopharmaceuticals: cancer and beyond	43
2020 update on the clinical validity of cerebrospinal fluid amyloid, tau, and phospho-tau as biomarkers for Alzheimer’s disease in the context of a structured 5-phase development framework	43
Head-to-head comparison of DFO* and DFO chelators: selection of the best candidate for clinical 89Zr-immuno-PET	43
Radioembolization of hepatocarcinoma with 90Y glass microspheres: treatment optimization using the dose-toxicity relationship	43
Performance of [68Ga]Ga-PSMA-11 PET/CT in patients with recurrent prostate cancer after prostatectomy—a multi-centre evaluation of 2533 patients	43
Artificial intelligence enables whole-body positron emission tomography scans with minimal radiation exposure	43
Structural and metabolic brain abnormalities in COVID-19 patients with sudden loss of smell	42
[18F]FDG and [68Ga]Ga-DOTA-FAPI-04 PET/CT in the evaluation of tuberculous lesions	42
Additional value of metabolic parameters to PET/CT-based radiomics nomogram in predicting lymphovascular invasion and outcome in lung adenocarcinoma	42
A multicenter comparison of [18F]flortaucipir, [18F]RO948, and [18F]MK6240 tau PET tracers to detect a common target ROI for differential diagnosis	42
Clinical insignificance of [18F]PSMA-1007 avid non-specific bone lesions: a retrospective evaluation	41
Image quality and lesion detectability in low-dose pediatric 18F-FDG scans using total-body PET/CT	41
FDG PET/CT for tumoral and systemic immune response monitoring of advanced melanoma during first-line combination ipilimumab and nivolumab treatment	41
Diagnostic performance of 68Ga-PSMA-11 PET/MRI-guided biopsy in patients with suspected prostate cancer: a prospective single-center study	41
Total-body 18F-FDG PET/CT scan in oncology patients: how fast could it be?	41
Position paper of the EACVI and EANM on artificial intelligence applications in multimodality cardiovascular imaging using SPECT/CT, PET/CT, and cardiac CT	41
A 3D deep learning model to predict the diagnosis of dementia with Lewy bodies, Alzheimer’s disease, and mild cognitive impairment using brain 18F-FDG PET	40
Improving staging of rectal cancer in the pelvis: the role of PET/MRI	39
High fibroblast-activation-protein expression in castration-resistant prostate cancer supports the use of FAPI-molecular theranostics	39
Current status and quality of radiomic studies for predicting immunotherapy response and outcome in patients with non-small cell lung cancer: a systematic review and meta-analysis	39
PET/CT radiomics signature of human papilloma virus association in oropharyngeal squamous cell carcinoma	39
COVID-19 pneumonia: relationship between inflammation assessed by whole-body FDG PET/CT and short-term clinical outcome	39
Joint EANM/SNMMI guideline on radiomics in nuclear medicine	39
Extensive preclinical evaluation of lutetium-177-labeled PSMA-specific tracers for prostate cancer radionuclide therapy	38
The added value of PSMA PET/MR radiomics for prostate cancer staging	38
Comparison of [68 Ga]Ga-DOTA-FAPI-04 PET/CT and [18F]FDG PET/CT in colorectal cancer	38
Comprehensive evaluation of 68Ga-PSMA-11 PET/CT parameters for discriminating pathological characteristics in primary clear-cell renal cell carcinoma	38
Dosing 225Ac-DOTATOC in patients with somatostatin-receptor-positive solid tumors: 5-year follow-up of hematological and renal toxicity	37
Measuring response in metastatic castration-resistant prostate cancer using PSMA PET/CT: comparison of RECIST 1.1, aPCWG3, aPERCIST, PPP, and RECIP 1.0 criteria	37
Use of radiomics based on 18F-FDG PET/CT and machine learning methods to aid clinical decision-making in the classification of solitary pulmonary lesions: an innovative approach	37
Prospective intra-individual blinded comparison of [18F]PSMA-1007 and [68 Ga]Ga-PSMA-11 PET/CT imaging in patients with confirmed prostate cancer	36
Early-phase [18F]PI-2620 tau-PET imaging as a surrogate marker of neuronal injury	36
Non-malignant findings of focal 68Ga-FAPI-04 uptake in pancreas	36
TSPO imaging in animal models of brain diseases	36
New PET technologies – embracing progress and pushing the limits	35
Clinical feasibility and impact of fully automated multiparametric PET imaging using direct Patlak reconstruction: evaluation of 103 dynamic whole-body 18F-FDG PET/CT scans	35
Assessing immune organs on 18F-FDG PET/CT imaging for therapy monitoring of immune checkpoint inhibitors: inter-observer variability, prognostic value and evolution during the treatment course of mela	35
Uncovering the invisible—prevalence, characteristics, and radiomics feature–based detection of visually undetectable intraprostatic tumor lesions in 68GaPSMA-11 PET images of patients with primary pro	35
Sequential implementation of DSC-MR perfusion and dynamic [18F]FET PET allows efficient differentiation of glioma progression from treatment-related changes	35
Clinical validity of increased cortical uptake of [18F]flortaucipir on PET as a biomarker for Alzheimer’s disease in the context of a structured 5-phase biomarker development framework	35
177 Lu-PSMA-617 radioligand therapy of metastatic castration-resistant prostate cancer: Initial 254-patient results from a prospective registry (REALITY Study)	35
[68Ga]Ga-DOTA-FAPI-04 PET/CT in the evaluation of gastric cancer: comparison with [18F]FDG PET/CT	35
Intra-therapeutic dosimetry of [177Lu]Lu-PSMA-617 in low-volume hormone-sensitive metastatic prostate cancer patients and correlation with treatment outcome	35
Quantification of amyloid PET for future clinical use: a state-of-the-art review	35
Biodistribution and dosimetry of a single dose of albumin-binding ligand [177Lu]Lu-PSMA-ALB-56 in patients with mCRPC	35
Tau PET imaging with 18F-PI-2620 in aging and neurodegenerative diseases	34
Random survival forest to predict transplant-eligible newly diagnosed multiple myeloma outcome including FDG-PET radiomics: a combined analysis of two independent prospective European trials	34
Value of 18F-FDG PET/CT radiomic features to distinguish solitary lung adenocarcinoma from tuberculosis	34
Dosimetry and safety of 177Lu PSMA-617 along with polyglutamate parotid gland protector: preliminary results in metastatic castration-resistant prostate cancer patients	34
Efficacy and safety of 225Ac-DOTATATE targeted alpha therapy in metastatic paragangliomas: a pilot study	33
Combination of terbium-161 with somatostatin receptor antagonists—a potential paradigm shift for the treatment of neuroendocrine neoplasms	33
Whole liver segmentation based on deep learning and manual adjustment for clinical use in SIRT	33
Clinical validity of second-generation tau PET tracers as biomarkers for Alzheimer’s disease in the context of a structured 5-phase development framework	33
[68Ga]Ga-DOTA-FAPI-04 improves tumor staging and monitors early response to chemoradiotherapy in a patient with esophageal cancer	33
Equivalent tumor detection for early and late FAPI-46 PET acquisition	33

How molecular imaging will enable robotic precision surgery	32
68Ga-PSMA Cerenkov luminescence imaging in primary prostate cancer: first-in-man series	32
Radiomics in pancreatic neuroendocrine tumors: methodological issues and clinical significance	32
Ventilation/perfusion SPECT/CT findings in different lung lesions associated with COVID-19: a case series	32
Novel FAP ligands enable improved imaging contrast in sarcoma patients due to FAPI-PET/CT	32
ImmunoPET imaging of multiple myeloma with [68Ga]Ga-NOTA-Nb1053	32
FAP imaging in rare cancer entities—first clinical experience in a broad spectrum of malignancies	32
EANM guideline on the role of 2-[18F]FDG PET/CT in diagnosis, staging, prognostic value, therapy assessment and restaging of ovarian cancer, endorsed by the American College of Nuclear Medicine (ACNM)	32
[18F]FDG PET radiomics to predict disease-free survival in cervical cancer: a multi-scanner/center study with external validation	32
Relationship between PET metabolism and SEEG epileptogenicity in focal lesional epilepsy	31
Advanced analytics and artificial intelligence in gastrointestinal cancer: a systematic review of radiomics predicting response to treatment	31
Targeted optical fluorescence imaging: a meta-narrative review and future perspectives	31
A comprehensive review of imaging findings in COVID-19 - status in early 2021	31
Targeting fibroblast activation protein in newly diagnosed squamous cell carcinoma of the oral cavity – initial experience and comparison to [18F]FDG PET/CT and MRI	31
Joint EANM/SNMMI procedure guideline for the use of 177Lu-labeled PSMA-targeted radioligand-therapy (177Lu-PSMA-RLT)	31
Comparison of the diagnostic efficacy of 68 Ga-FAPI-04 PET/MR and 18F-FDG PET/CT in patients with pancreatic cancer	31
Relationship between amyloid and tau levels and its impact on tau spreading	30
A global evaluation of advanced dosimetry in transarterial radioembolization of hepatocellular carcinoma with Yttrium-90: the TARGET study	30
Application of artificial intelligence in nuclear medicine and molecular imaging: a review of current status and future perspectives for clinical translation	30
Phase II trial demonstrates the efficacy and safety of individualized, dosimetry-based 177Lu-DOTATATE treatment of NET patients	30
False positive PSMA PET for tumor remnants in the irradiated prostate and other interpretation pitfalls in a prospective multi-center trial	30
Complete remission of follicular lymphoma after SARS-CoV-2 infection: from the “flare phenomenon” to the “abscopal effect”	30
Translational imaging of the fibroblast activation protein (FAP) using the new ligand [68Ga]Ga-OncoFAP-DOTAGA	30
Machine learning based on clinico-biological features integrated 18F-FDG PET/CT radiomics for distinguishing squamous cell carcinoma from adenocarcinoma of lung	30
COVID-19 vaccine as a cause for unilateral lymphadenopathy detected by 18F-FDG PET/CT in a patient affected by melanoma	29
Generalization of deep learning models for ultra-low-count amyloid PET/MRI using transfer learning	29
Impact of the COVID-19 pandemic in nuclear medicine departments: preliminary report of the first international survey	29
A deep neural network for fast and accurate scatter estimation in quantitative SPECT/CT under challenging scatter conditions	29
Sigma-1 and dopamine D2/D3 receptor occupancy of pridopidine in healthy volunteers and patients with Huntington disease: a [18F] fluspidine and [18F] fallypride PET study	29
Image enhancement of whole-body oncology [18F]-FDG PET scans using deep neural networks to reduce noise	29
Theranostic implications of molecular imaging phenotype of well-differentiated pulmonary carcinoid based on 68Ga-DOTATATE PET/CT and 18F-FDG PET/CT	28
The impact of demographic, clinical, genetic, and imaging variables on tau PET status	28
PET/CT-based radiomics of mass-forming intrahepatic cholangiocarcinoma improves prediction of pathology data and survival	28
Clinical utility of perfusion (Q)-single-photon emission computed tomography (SPECT)/CT for diagnosing pulmonary embolus (PE) in COVID-19 patients with a moderate to high pre-test probability of PE	28
True ultra-low-dose amyloid PET/MRI enhanced with deep learning for clinical interpretation	28
Regional [18F]flortaucipir PET is more closely associated with disease severity than CSF p-tau in Alzheimer’s disease	28
Oxford-AstraZeneca COVID-19 vaccination induced lymphadenopathy on [18F]Choline PET/CT—not only an FDG finding	28
Prediction of TERTp-mutation status in IDH-wildtype high-grade gliomas using pre-treatment dynamic [18F]FET PET radiomics	28
AI-enhanced simultaneous multiparametric 18F-FDG PET/MRI for accurate breast cancer diagnosis	28
Fibroblast activation protein imaging in reperfused ST-elevation myocardial infarction: comparison with cardiac magnetic resonance imaging	28
[68 Ga]Ga-FAPI-46 PET for non-invasive detection of pulmonary fibrosis disease activity	28
Combined use of 177Lu-DOTATATE and metronomic capecitabine (Lu-X) in FDG-positive gastro-entero-pancreatic neuroendocrine tumors	28
Fatty acid-conjugated radiopharmaceuticals for fibroblast activation protein-targeted radiotherapy	28
Diagnostic performance of preoperative [18F]FDG-PET/CT for lymph node staging in vulvar cancer: a large single-centre study	28
Comparison of nodal staging between CT, MRI, and [18F]-FDG PET/MRI in patients with newly diagnosed breast cancer	28
Global experience with PSMA-based alpha therapy in prostate cancer	28
Increased uptake of 68Ga-DOTA-FAPI-04 in bones and joints: metastases and beyond	28
Radiomic analysis of magnetic resonance fingerprinting in adult brain tumors	28
Differential associations of APOE-ε2 and APOE-ε4 alleles with PET-measured amyloid-β and tau deposition in older individuals without dementia	27
Response and outcome of liver metastases in patients with metastatic castration-resistant prostate cancer (mCRPC) undergoing 177Lu-PSMA-617 radioligand therapy	27
Sentinel lymph node detection in oral cancer: a within-patient comparison between [99mTc]Tc-tilmanocept and [99mTc]Tc-nanocolloid	27
Phase I study to assess safety, biodistribution and radiation dosimetry for 89Zr-girentuximab in patients with renal cell carcinoma	27
Correlation between BNT162b2 mRNA Covid-19 vaccine-associated hypermetabolic lymphadenopathy and humoral immunity in patients with hematologic malignancy	27
A CT-based radiomics model to detect prostate cancer lymph node metastases in PSMA radioguided surgery patients	27
Deep learning-based image reconstruction and post-processing methods in positron emission tomography for low-dose imaging and resolution enhancement	27
The value of 18F-FDG PET/CT for the diagnosis of device-related infections in patients with a left ventricular assist device: a systematic review and meta-analysis	27
Head-to-head evaluation of [18F]FDG and [68 Ga]Ga-DOTA-FAPI-04 PET/CT in recurrent soft tissue sarcoma	27
The deep learning model combining CT image and clinicopathological information for predicting ALK fusion status and response to ALK-TKI therapy in non-small cell lung cancer patients	27
[18F]AlF-NOTA-FAPI-04 PET/CT uptake in metastatic lesions on PET/CT imaging might distinguish different pathological types of lung cancer	27
68Ga-PSMA-11 PET/CT in recurrent hormone-sensitive prostate cancer (HSPC): a prospective single-centre study in patients eligible for salvage therapy	26
18F-PSMA-1007 PET/CT for response assessment in patients with metastatic renal cell carcinoma undergoing tyrosine kinase or checkpoint inhibitor therapy: preliminary results	26
First-in-human evaluation of [11C]PS13, a novel PET radioligand, to quantify cyclooxygenase-1 in the brain	26
Distinguishing nontuberculous mycobacteria from Mycobacterium tuberculosis lung disease from CT images using a deep learning framework	26
[18F]FDG PET-CT in patients with DLBCL treated with CAR-T cell therapy: a practical approach of reporting pre- and post-treatment studies	26
Visual interpretation of brain hypometabolism related to neurological long COVID: a French multicentric experience	26
Performance of the PET vascular activity score (PETVAS) for qualitative and quantitative assessment of inflammatory activity in Takayasu’s arteritis patients	26
[18F]AlF-NOTA-FAPI-04: FAP-targeting specificity, biodistribution, and PET/CT imaging of various cancers	26
Augmented deep learning model for improved quantitative accuracy of MR-based PET attenuation correction in PSMA PET-MRI prostate imaging	26
Kinetic modeling and parameter estimation of TSPO PET imaging in the human brain	26
CSF p-tau/Aβ42 ratio and brain FDG-PET may reliably detect MCI “imminent” converters to AD	26
Tau pathology and relative cerebral blood flow are independently associated with cognition in Alzheimer’s disease	26
Prospective comparison of 18F-PSMA-1007 PET/CT, whole-body MRI and CT in primary nodal staging of unfavourable intermediate- and high-risk prostate cancer	26
Deep learning radiomics of dual-energy computed tomography for predicting lymph node metastases of pancreatic ductal adenocarcinoma	25
PET/MRI assessment of lung nodules in primary abdominal malignancies: sensitivity and outcome analysis	25
Intraindividual comparison between 68Ga-PSMA-PET/CT and mpMRI for intraprostatic tumor delineation in patients with primary prostate cancer: a retrospective analysis in 101 patients	25
Microvascular dysfunction and sympathetic hyperactivity in women with supra-normal left ventricular ejection fraction (snLVEF)	25
Cyclotron production of 225Ac from an electroplated 226Ra target	25
Hybrid PET/MRI in non-small cell lung cancer (NSCLC) and lung nodules—a literature review	25
Visual assessment of [18F]flutemetamol PET images can detect early amyloid pathology and grade its extent	25
Time-dependent recovery of brain hypometabolism in neuro-COVID-19 patients	25
Evidence-based guideline of the European Association of Nuclear Medicine (EANM) on imaging infection in vascular grafts	25
Feasibility of late acquisition [68Ga]Ga-PSMA-11 PET/CT using a long axial field-of-view PET/CT scanner for the diagnosis of recurrent prostate cancer—first clinical experiences	25
Real-time intraoperative glioma diagnosis using fluorescence imaging and deep convolutional neural networks	25
Multivariate radiomics models based on 18F-FDG hybrid PET/MRI for distinguishing between Parkinson’s disease and multiple system atrophy	25
Parametric image generation with the uEXPLORER total-body PET/CT system through deep learning	25
Preclinical evaluation of [225Ac]Ac-DOTA-TATE for treatment of lung neuroendocrine neoplasms	25
Fibroblast activation protein-targeted radionuclide therapy: background, opportunities, and challenges of first (pre)clinical studies	25
To 1000 Gy and back again: a systematic review on dose-response evaluation in selective internal radiation therapy for primary and secondary liver cancer	25
Kinetic metrics of 18F-FDG in normal human organs identified by systematic dynamic total-body positron emission tomography	25
Clinical outcome of PSMA-guided radiotherapy for patients with oligorecurrent prostate cancer	25
177Lu-PSMA-617 versus docetaxel in chemotherapy-naïve metastatic castration-resistant prostate cancer: a randomized, controlled, phase 2 non-inferiority trial	25
NEMA NU2-2012 performance measurements of the United Imaging uPMR790: an integrated PET/MR system	25
Matched-pair analysis of [177Lu]Lu-PSMA I&T and [177Lu]Lu-PSMA-617 in patients with metastatic castration-resistant prostate cancer	25
PET/CT imaging for evaluation of multimodal treatment efficacy and toxicity in advanced NSCLC—current state and future directions	25
Temporal trajectories of in vivo tau and amyloid-β accumulation in Alzheimer’s disease	24